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Because -catenin target genes such as cyclin D1 are
involved in cell cycle progression, we examined whether
-catenin has a more pervasive role in normal cell pro-
liferation, even upon stimulation by non-Wnt ligands.
Here, we demonstrate that epidermal growth factor
(EGF) stimulates T-cell factor/lymphoid enhancer factor
(Tcf/Lef) transcriptional activity in nontransformed
mammary epithelial cells (MCF-10A) and that its tran-
scriptional activity is essential for EGF-mediated pro-
gression through G1/S phase. Thus, expression of domi-
nant-negative Tcf4 blocks EGF-mediated Tcf/Lef
transcriptional activity and bromodeoxyuridine uptake.
In fact, the importance of EGF-mediated Tcf/Lef tran-
scriptional activity for cell cycle progression may lie
further upstream at the G1/S phase transition. We dem-
onstrate that dominant-negative Tcf4 inhibits a reporter
of cyclin D1 promoter activity in a dose-dependent man-
ner. Importantly, dominant-negative Tcf4 suppresses
EGF-mediated cell cycle activity specifically by thwart-
ing EGF-mediated Tcf/Lef transcriptional activity, not
by broader effects on EGF signaling. Thus, although
expression of dominant-negative Tcf4 blocks EGF-medi-
ated TOPFLASH activation, it has no effect on either
EGF receptor or ERK phosphorylation, further under-
scoring the fact that Tcf/Lef-mediated transcription is
essential for cell cycle progression, even when other
pro-mitogenic signals are at normal levels. Yet, despite
its essential role, Tcf/Lef transcriptional activity alone
is not sufficient for cell cycle progression. Serum also
stimulates Tcf/Lef transcriptional activation in MCF-
10A cells but is unable to promote DNA synthesis. Taken
together, our data support a model wherein EGF pro-
motes Tcf/Lef transcriptional activity, and this signal is
essential but not sufficient for cell cycle activity.
-Catenin is a 90-kDa intracellular protein whose functions
range from stabilization of cell-cell adhesion to control over
gene expression. These functions are tightly regulated through
its association with various proteins such as the transmem-
brane protein E-cadherin and Tcf/Lef1 transcription factors (1,
2). E-cadherin is a major constituent of adherens junctions
where it promotes epithelial cell-cell contact through homo-
typic interactions mediated by its extracellular domain (3).
Meanwhile, its cytoplasmic domain binds to -catenin, whose
association with -catenin and other structural proteins
bridges E-cadherin-mediated contacts to the actin cytoskeleton
(4). In addition to regulation by sequestration to the plasma
membrane, -catenin is tightly regulated by cytosolic degrada-
tion via a multiprotein complex consisting of Axin, APC, and
glycogen synthase kinase 3 (GSK3) (5). Signaling events
that inhibit this cytosolic degradation machinery, such as those
initiated by a subset of Wnt family ligands, help to stabilize
-catenin, which then translocates to the nucleus where it
serves as a transactivator for the Tcf/Lef family of transcription
factors.
Mutations that abnormally stabilize -catenin occur in a
diverse range of cancer types. In colorectal carcinomas and
melanomas, these mutations include the loss and/or truncation
of APC or mutations among critical N-terminal serine residues
of -catenin whose phosphorylation flags it for ubiquitin-medi-
ated degradation (5–7). Evidence of -catenin stabilization has
also been shown in hepatomas and prostate cancers wherein
loss of axin and PTEN, respectively, leads to accumulation of
nuclear -catenin and increased Tcf/Lef-mediated transcrip-
tion (8, 9). In the mammary gland, transgenic expression of
Wnt family ligands induces mammary adenocarcinomas in
mice (10). Consistent with this finding, mammary tissue-spe-
cific overexpression of a constitutively stable -catenin mutant
induces hyperplasia and adenocarcinoma in the mammary
gland (11). Finally, studies using stabilized mutants of -cate-
nin or Tcf/Lef-VP16 fusion constructs have affirmed the capac-
ity of this signaling pathway to transform established cell lines
and primary cells (12–14).
In fact, antagonizing -catenin signaling appears to be an
effective method to curb the growth of cancer cell lines afflicted
by elevated levels of nuclear -catenin. Exogenous expression
of APC, axin, or PTEN reinstates -catenin turnover and sup-
presses growth of hepatocellular and prostate carcinoma cells
(8, 9). Inhibition of integrin-linked kinase, a serine/threonine
kinase that inhibits GSK3 and thereby stabilizes -catenin,
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reduces growth in prostate cancer lines (15). Finally, overex-
pression of proteins, such as full-length E-cadherin or a trun-
cated mutant possessing just the C-terminal /-catenin-bind-
ing domain, sequesters stabilized -catenin, precludes its
association with Tcf/Lef transcription factors, and effectively
inhibits proliferation of colorectal cancer cell lines (16–18).
Although the transformation potential of -catenin has been
closely examined, the role of -catenin and Tcf/Lef transcrip-
tion factors in cell cycle progression among normal mammalian
cells is beginning to emerge. Immunohistochemical data have
shown that self-propagating precursor cells in the intervillus
regions of the small intestine epithelium, but not the well
differentiated cells at the villi tip, exhibit nuclear -catenin
and express several Tcf/Lef target genes, including c-myc and
CD44 (19). In addition, Tcf4 knock-out mice lack proliferating
stem cells and possess only differentiated villus cells, suggest-
ing a causal role for Tcf/Lef in governing stem cell lineage
commitment (20). In addition to intestinal epithelia, Tcf/Lef
signaling is involved in lineage commitment of human epider-
mal stem cells (21, 22), neural precursors (23–25), hematopoi-
etic stem cells (26), and embryonic stem cells (27). However, the
ligand(s) implicated in stimulating Tcf/Lef signaling and dic-
tating stem cell fate are largely unknown, although Wnt is
clearly involved in some instances (26, 28).
It is unclear whether non-Wnt ligands also utilize the Tcf/Lef
pathway to regulate proliferation. Recently, a correlation be-
tween serum-mediated proliferation and Tcf/Lef transcrip-
tional activity has been suggested in a study using an engi-
neered mammary cell system (29). These cells express a c-Fos-
estradiol receptor fusion protein that permits switching from
epithelial to fibroblastoid phenotype upon estradiol-mediated
activation of c-Fos (30). In both phenotypes, conditions that
inhibited proliferation such as serum starvation also down-
regulated -catenin transcriptional activity. However, a causal
role for -catenin in serum-induced cell cycle progression was
not clearly established in the epithelial cell phenotype. Taken
together, inducible activation of c-Fos, which is a component of
the AP-1 transcriptional machinery and itself critically in-
volved in cell cycle control (31), and the inability of -catenin
suppression to consistently inhibit proliferation preclude an
assessment of whether -catenin nuclear activity is mechanis-
tically involved in proliferation.
Interestingly, several reports have indicated that specific
growth factors such as insulin-like growth factor I and insulin
induce -catenin transcriptional activity (32). Although these
studies were conducted with cancer cell lines lacking normal
-catenin degradation machinery, HGF and certain members
of the Wnt family of ligands induce -catenin transcriptional
activity in normal cells (33, 34). Although the importance of
HGF-mediated -catenin signaling for normal cell cycle pro-
gression has not been examined, certain members of the Wnt
family of ligands regulate proliferation in a -catenin-depend-
ent manner (35). Nevertheless, because -catenin target genes
include c-myc and cyclin D1, whose protein products are ubiq-
uitously crucial for cell cycle progression (36–38), the untested
hypothesis remains that -catenin has a more pervasive role in
normal epithelial cell proliferation, even in response to growth-
stimulating cues from non-Wnt ligands.
We examined this hypothesis pertaining to the role of -cate-
nin in cell cycle progression in the normal mammary epithelial
cell line MCF-10A. We demonstrate that EGF stimulates Tcf/
Lef transcriptional activity and that this transcriptional activ-
ity is necessary but not sufficient for cell cycle progression of
normal epithelial cells. Thus, inhibition of Tcf/Lef transcrip-
tional activity using dominant-negative Tcf4 prevents EGF-
mediated cell cycle progression. Since dominant-negative Tcf4
inhibits cyclin D1 promoter activity and BrdU uptake without
affecting other EGF-mediated signals such as ERK that also
regulate proliferation, we conclude that Tcf/Lef-mediated tran-
scription is required for cell cycle progression.
EXPERIMENTAL PROCEDURES
Antibodies—The following antibodies were used in this study: anti-
actin (Santa Cruz), anti-BrdU (Roche Applied Science), anti-ERK2
(Santa Cruz), anti-GSK3 (BD Transduction Laboratories), anti-phos-
pho-Ser9-GSK3 (BIOSOURCE), monoclonal and polyclonal anti-
FLAG (Sigma), anti-phospho-ERK1/2 (Thr202/Tyr204) (Cell Signaling
Technology), anti-phosphotyrosine (Santa Cruz), and anti-Tcf4 (Up-
state Biotechnology, Inc.).
Cell Culture—SW480 cells were cultured in Dulbecco’s modified Ea-
gle’s medium supplemented with 4 mM L-glutamine (Invitrogen), 10%
(v/v) fetal bovine serum (Invitrogen), and 1% (v/v) penicillin/streptomy-
cin (Invitrogen). MCF-10A cells were cultured in Dulbecco’s modified
Eagle’s medium/Ham’s F-12 containing HEPES and L-glutamine (In-
vitrogen) supplemented with 5% (v/v) horse serum (Invitrogen), 20
ng/ml EGF (Peprotech), 0.5 g/ml hydrocortisone (Sigma), 0.1 g/ml
cholera toxin (Sigma), 10 g/ml insulin (Sigma), and 1% penicillin/
streptomycin. For serum starvation, the cells were washed twice in PBS
and then cultured in Dulbecco’s modified Eagle’s medium/Ham’s F-12
supplemented with 1% (v/v) penicillin/streptomycin and 0.1% bovine
serum albumin (Sigma) for 24 h.
Plasmid Constructs—pcDNA-myc-N-Tcf4 was generously provided
by K. W. Kinzler (Johns Hopkins University) (7). pPGS and pPGS-N-
Tcf4 were kindly donated by E. Fearon (University of Michigan, Ann
Arbor) (13). VSV-G and gag-pol vectors were gifts from D. Schaffer
(University of California, Berkeley). Luciferase-based reporters pTOP-
FLASH and pFOPFLASH were purchased from Upstate Biotechnology,
Inc., whereas 1745CD1 was a gift from R. Pestell (Georgetown Univer-
sity, Washington, D.C.) (39).
Retroviral Infection—Retrovirus was produced by either by single
transfection of the packaging cell line 293GPG with 15 g of retroviral
plasmid (40) or by triple transfection of 293T cells with 5 g each of
VSV-G, gag-pol and a retroviral vector using LipofectAMINE (Invitro-
gen). For infection, MCF-10A cells were incubated with retrovirus-
containing medium and 8 g/ml polybrene for 24 h.
GSK3 Serine 9 Phosphorylation Assay—MCF-10A cells were plated
at a subconfluent density (105 cells/35-mm dish) and allowed to adhere
for 48 h, followed by serum starvation for 24 h. The cells were stimu-
lated with either full growth medium or serum-free medium supple-
mented with either 10 g/ml insulin or 20 ng/ml EGF and then lysed in
modified RIPA buffer at desired times.
ERK Signaling Assay—MCF-10A cells were plated at a subconfluent
density (105 cells/35-mm dish), allowed to adhere for 24 h, and then
infected with retrovirus encoding pPGS or pPGS-FLAG-N-Tcf4 at
multiplicity of infection equal to 1. Twenty-four hours after infection,
the cells were starved in serum-free medium for 24 h, stimulated with
20 ng/ml EGF in serum-free medium, and then lysed in modified RIPA
buffer at desired times.
Cell Lysis—The stimulated cells were washed twice in ice-cold PBS
and scraped into cold lysis buffer. After incubating on ice for 15 min, the
cell lysates were clarified by centrifugation, and the supernatant was
collected as whole cell lysate. The protein concentrations were deter-
mined using BCA reagents (Sigma). The samples prepared to assay
EGF-mediated activation of the ERK pathway were lysed in modified
RIPA buffer (50 mM Tris-Cl (pH 7.5) 150 mM NaCl, 1% Triton X-100,
0.5% Nonidet P-40, 0.25% sodium deoxycholate, 50 mM -glycerophos-
phate (pH 7.3) 10 mM NaPP, 30 mM NaF, 1 mM benzamidine, 2 mM
EGTA, 1 mM sodium orthovanadate, 1 mM dithiothreitol, 5 g/ml apro-
tinin, 5 g/ml leupeptin, 1 g/ml pepstatin, and 1 mM phenylmethyl-
sulfonyl fluoride). Finally, cell lysis for all reporter measurements was
performed in 1 passive lysis buffer provided by the manufacturer
(Promega).
Reporter Assays—SW480 or MCF-10A cells were plated at a subcon-
fluent density (105 cells/35-mm dish) and co-transfected with 1 g of the
appropriate reporter and 0.1 g of pRL-TK using FuGENE 6 (Roche
Applied Science). SW480 cells were always maintained in growth me-
dium and lysed 48 h after transfection. Meanwhile, MCF-10A cells were
serum-starved for 24 h, stimulated with appropriate medium, and lysed
at desired times. In both cases, reporter activity was measured using
the dual luciferase assay according to the manufacturer instructions
(Promega). To normalize for potential variations in transfection or lysis
efficiency, luciferase signals were normalized to control Renilla lucifer-
ase signal.
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Integrated Reporter Response—The reporter signal response above
its initial value was integrated numerically over time as follows,

0
12
Rt  Rt0dt  12
k1
n
Rtk  Rtk1  n  1Rt0 t
(Eq. 1)
where R(t) is the reporter signal, R(t0) is its basal, initial value, tk is the
time ranging from 0 to 12 h in discrete intervals of t (3 h), n is the
number of time points (n  5), and k is the index of summation.
Western Blotting—Whole cell lysates were resolved by SDS-PAGE on
7.5–10% gels and blotted onto polyvinylidene difluoride membrane (Bio-
Rad). The membranes were blocked overnight and then incubated se-
quentially with primary and corresponding horseradish peroxidase-
conjugated secondary antibody. The blots were treated with
SuperSignal West Femto Substrate (Pierce) and imaged on VersaDoc
3000 (Bio-Rad) using Quantity One software (Bio-Rad).
DNA Synthesis—DNA synthesis was assayed by either [3H]thymi-
dine or BrdU incorporation. In both cases, MCF-10A cells were seeded
at the indicated cell densities. After 24 h, the cells were either infected
with retrovirus or left in growth medium. On the following day, the cells
were serum-starved. Notably, the 48 h of duration between cell seeding
and serum starvation was chosen to match the time required for plating
and transfecting cells in reporter assays, allowing direct comparison
between DNA synthesis and reporter experiments. Following 24 h of
serum starvation, the cells were stimulated with appropriate medium.
Sixteen hours after stimulation, the medium was replaced with identi-
cal medium supplemented with either 10 Ci/ml [3H]thymidine (ICN
Biomedicals) or 10 mol/liter BrdU (Roche Applied Science) and further
incubated for 6 h. In the case of [3H]thymidine incorporation, the cells
were washed twice in ice-cold PBS, incubated in 5% trichloroacetic acid
for 20 min at 4 °C, washed twice with cold 70% ethanol, and incubated
with 0.1 M NaOH, 2% Na2CO3, and 1% SDS for 30 min at 37 °C. The
solution was collected and mixed with CytoScint (ICN Biomedicals) for
scintillation counting. For BrdU detection, the cells were fixed and
co-stained with DAPI, anti-BrdU antibody, and polyclonal anti-FLAG
antibody. The number of nuclei stained positive for BrdU and FLAG
were quantified in 3–10 different fields on 2–5 independent trials using
the Zeiss Axiovert 200M microscope.
Immunofluorescence—For Tcf/FLAG co-staining, the cells grown on
glass coverslips were washed three times in ice-cold PBS, fixed in 4%
formalin in PBS, and permeabilized in 0.2% Triton X-100. After block-
ing overnight in BB (10% goat serum, 0.1% bovine serum albumin in
PBS), the coverslips were sequentially incubated with primary and
corresponding Alexa dye-labeled secondary antibodies (Molecular
Probes). Following antibody incubations, the coverslips were stained
with DAPI (Sigma) and mounted using Prolong Anti-Fade (Molecular
Probes).
For BrdU/FLAG co-staining, the cells were fixed and permeabilized
in 4% formalin and 0.2% Triton X-100, respectively, and then incubated
with polyclonal FLAG antibody and Alexa 594-conjugated secondary
antibody. The antibodies were then fixed in 4% formalin, followed by a
second fixation in 15 mM glycine in 70% ethanol (pH 2). The coverslips
were incubated with monoclonal BrdU antibody and then Alexa 488-
conjugated secondary antibody, stained with DAPI, and mounted as
described above.
RESULTS
Re-entry into the Cell Cycle Correlates with Tcf/Lef Reporter
Activity—Target genes for Tcf/Lef include cyclin D1 and c-myc,
suggesting a role for this family of transcription factors in cell
cycle progression not only among cancer cells with stabilized
nuclear -catenin, but also among normal epithelial cells.
Therefore, we determined whether a correlation exists between
Tcf/Lef transcriptional activity and cell cycle progression in
nontransformed mammary epithelial (MCF-10A) cells. Tcf/Lef
transcriptional activity was monitored with TOPFLASH re-
porter (7), a plasmid containing consensus Tcf-binding sites
upstream of the luciferase gene. In contrast, the negative con-
trol FOPFLASH reporter carries mutations at these Tcf/Lef-
binding sites. Performance of TOPFLASH and FOPFLASH
reporters was confirmed in SW480 colon carcinoma cells in
which TOPFLASH, but not FOPFLASH, is constitutively ac-
tive because of a truncation of the APC gene and consequent
stabilization of -catenin (7) (Fig. 1A).
Subconfluent MCF-10A cells transfected with TOPFLASH or
FOPFLASH reporters were growth-arrested by serum starva-
tion and then stimulated to re-enter the cell cycle by treatment
with growth medium. As shown in Fig. 1B, growth medium
stimulation activated TOPFLASH reporter, which gradually
increased to a near-maximum level within the first 9 h. Mean-
while, FOPFLASH negative control reporter did not respond to
growth medium stimulation. Taken together, this establishes a
correlation between re-entry into the cell cycle and Tcf/Lef-
mediated transcription.
To confirm further that the observed TOPFLASH signal was
FIG. 1. TOPFLASH and FOPFLASH reporter activity in SW480
and MCF-10A cells. A, TOPFLASH, but not FOPFLASH, reporter is
triggered in SW480 colon carcinoma cells. SW480 cells were co-trans-
fected with 0.1 g of pRL-TK and 1 g of either TOPFLASH or FOP-
FLASH. Forty-eight hours after transfection, the cells were lysed, and
the ratio of luciferase to Renilla luciferase signal was quantified. B,
TOPFLASH, but not FOPFLASH, reporter is activated upon growth
medium stimulation of normal mammary epithelial cells. MCF-10A
cells were co-transfected with 0.1 g of pRL-TK and 1 g of TOPFLASH
() or FOPFLASH (E). After serum starvation, the cells were stimu-
lated with growth medium and luciferase:Renilla luciferase signal ratio
was quantified at desired time points. Reporter activity relative to the
TOPFLASH response at 6 h is shown. The error bars represent  S.E.
from two to five independent experiments. The asterisk denotes p 	
0.05 (Student’s t test) in comparing TOPFLASH signal to the zero time
response.
FIG. 2. Dominant-negative Tcf4 effect on TOPFLASH reporter.
A, dominant-negative Tcf4 inhibits TOPFLASH signal in SW480 colon
carcinoma cells. SW480 cells were co-transfected with 1 g of TOP-
FLASH, 0.1 g of pRL-TK, and either 0.5 g of empty vector (pcDNA)
or dominant-negative Tcf4 (N-Tcf4). Forty-eight hours after transfec-
tion, the luciferase:Renilla luciferase signal ratio was quantified. B,
dominant-negative Tcf4 inhibits growth medium-mediated TOPFLASH
signal in MCF-10A cells. MCF-10A cells were co-transfected with 1 g
of TOPFLASH, 0.1 g of pRL-TK, and different amounts (0, 0.05, 0.1,
and 0.5 g) of dominant-negative Tcf4 (N-Tcf4), always with a balanc-
ing amount (0.5, 0.45, 0.4, and 0 g, respectively) of empty vector
(pcDNA). Serum-starved cells were stimulated with growth medium for
9 h, after which the luciferase:Renilla luciferase signal ratio was quan-
tified. Co-transfection with increasing amount of N-Tcf4 correspond-
ingly attenuated TOPFLASH induction by growth medium. The error
bars indicate  S.E. (n  3). The asterisk indicates p 	 0.01 (Student’s
t test).
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specifically monitoring Tcf/Lef transcription factor activity, a
dominant-negative Tcf4 construct (myc-N-Tcf4) was em-
ployed. This construct possesses the DNA-binding domain of
Tcf4 but lacks the N-terminal 31 amino acids that mediate its
association with its transactivating catenin partner (7). As
expected, dominant-negative Tcf4 inhibited TOPFLASH activ-
ity in SW480 cells (Fig. 2A). Co-transfection of N-Tcf4 into
MCF-10A cells decreased growth medium-induced TOPFLASH
response in a dose-dependent fashion (Fig. 2B), indicating that
the TOPFLASH signal was mediated specifically by Tcf/Lef
transcription factors.
EGF Independently Induces Tcf/Lef Transcriptional Activity
and DNA Synthesis—Because MCF-10A growth medium con-
tains a complex mixture of stimuli, including serum factors,
insulin, and EGF, it is unclear whether a single constituent is
capable of inducing Tcf/Lef transcriptional activity and, more-
over, whether the same constituent also functions as a mitogen.
To address this issue, the cells were stimulated with each
constituent of growth medium separately, and Tcf/Lef tran-
scriptional activity and DNA synthesis were assessed by meas-
uring TOPFLASH reporter signal and [3H]thymidine uptake,
respectively.
EGF independently induced TOPFLASH signal to a level
distinctly above the corresponding FOPFLASH control (Fig.
3A). At early time, EGF-mediated TOPFLASH signal mirrors
growth medium-induced TOPFLASH activity. However,
whereas full growth medium sustains TOPFLASH signal to
24 h (Fig. 1A), EGF promotes a transient signal that reaches its
peak intensity of nearly 3-fold above basal level at 3 h. Mean-
while, in contrast to EGF, insulin-mediated TOPFLASH acti-
vation more closely matches the FOPFLASH negative control,
except at 3 h where a transient signal that is 
50% of the
EGF-mediated TOPFLASH signal is observed. Taken together,
growth medium constituents quantitatively vary in their abil-
ity to promote Tcf/Lef transcriptional activity, with EGF, more
so than insulin, resembling the response to full growth
medium.
The current paradigm for Wnt-mediated Tcf/Lef transcrip-
tional activity involves inhibition of GSK3-mediated phospho-
rylation of -catenin, which in turn stabilizes -catenin and
ultimately enables its translocation into the nucleus (41–43).
Interestingly, both EGF and insulin have been reported to
inhibit GSK3 kinase activity toward primed substrates by
inducing phosphorylation of GSK3 at serine 9 (44–48). Be-
cause there is conflicting evidence as to whether -catenin
qualifies as a primed or nonprimed substrate of GSK3 (49–
52), we investigated whether EGF, insulin, and growth me-
dium affected GSK3 phosphorylation at serine 9 in a manner
that is quantitatively consistent with their differential effects
on Tcf/Lef transcriptional activity. Within 10 min of stimula-
tion, GSK3 was phosphorylated at serine 9 among serum-
starved MCF-10A cells in response to either insulin or EGF
FIG. 3. Growth medium constituents vary in the ability to in-
duce Tcf-Lef transcriptional activity, GSK3 phosphorylation,
and DNA synthesis. A, EGF transiently stimulates Tcf/Lef transcrip-
tional activity. MCF-10A cells were co-transfected with 0.1 g of
pRL-TK and 1 g of TOPFLASH (filled symbols, solid line) or FOP-
FLASH (open symbols, dotted line). After serum starvation, the cells
were stimulated with full growth medium ( and ) or serum-free
medium supplemented with 20 ng/ml EGF (f and ), 5% horse serum
(Œ and ‚) or 10 g/ml insulin ( and E). The concentration of each
supplement was chosen to match the concentration of the supplement
in growth medium. Luciferase:Renilla luciferase signal ratio was quan-
tified at the desired time points and is reported relative to its initial,
basal level. The error bars represent  S.E. from two to five independ-
ent experiments. B, insulin, EGF, and growth medium induce serine 9
phosphorylation of GSK3 with qualitatively distinct time courses.
Serum-starved MCF-10A cells were stimulated with either full growth
medium (GM) or serum-free medium supplemented with 10 g/ml
insulin or 20 ng/ml EGF and then lysed at indicated times. Western
blotting of cell lysates with a phospho-specific antibody shows that
serine 9 of GSK3 is phosphorylated within 10 min of stimulation with
insulin, EGF, or growth medium. After 10 min, the levels of phospho-
rylated GSK3 decrease in insulin-stimulated cells, whereas cells stim-
ulated with EGF show relatively more sustained phosphorylation (com-
pare the 30-min bands). Finally, the cells stimulated with growth me-
dium possess the most sustained phosphorylation response (compare
the 60-min bands). Taken together, EGF and growth medium promote
a longer lifetime of serine 9 phosphorylation of GSK3 than insulin.
Blotting with a total GSK3 antibody confirmed equal protein loading.
The data shown are representative of two independent trials. C, stimuli
that promote DNA synthesis also activate TOPFLASH reporter but not
all stimuli that induce TOPFLASH promote DNA synthesis. TOP-
FLASH data (white bars) are expressed as the integrated response over
a 12-h stimulation period. Both TOPFLASH reporter response and
[3H]thymidine incorporation (black bars) are expressed relative to the
EGF response. Although EGF, growth medium, and horse serum in-
duced significant TOPFLASH responses, only EGF and growth medium
stimulate [3H]thymidine incorporation.
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(Fig. 3B). However, in insulin-stimulated cells, dephosphoryl-
ation of GSK3 was evident by 60 min, whereas in EGF-
stimulated cells, serine 9 phosphorylation of GSK3 was more
sustained. Stimulation with growth medium, which contains
insulin, EGF, and serum factors, induced more sustained phos-
phorylation of GSK3 than either EGF or insulin alone. Taken
together, the stimuli (growth medium and EGF) that yield a
qualitatively durable phosphoserine 9 GSK3 signal also in-
duce stronger Tcf/Lef transcriptional activity. This correlation
suggests, but does not unequivocally demonstrate, a role for
serine 9 phosphorylation of GSK3 in EGF-mediated Tcf/Lef
transcriptional activity, further raising the issue of whether
-catenin is a primed or nonprimed substrate of GSK3.
Although ongoing work is focused on parsing the role of
serine 9 phosphorylation of GSK3 and other mechanisms by
which EGF stimulates TOPFLASH activity, we focused in this
work on understanding the downstream significance of EGF-
mediated Tcf/Lef transcriptional activity. Since the kinetics of
TOPFLASH reporter response varied among stimuli, we calcu-
lated the time integral of each signal as a single quantitative
metric capable of capturing effects on both signal magnitude
and dynamics (53). Using this metric, we determined whether
the ability to induce Tcf/Lef transcriptional activity quantita-
tively relates to the mitogenic potency of the stimulus as meas-
ured by DNA synthesis using a [3H]thymidine uptake assay.
EGF independently induces DNA synthesis and accounts for

70% of the mitogenic activity of complete growth medium
(Fig. 3C); insulin, however, fails to promote DNA synthesis.
Thus, the ability of EGF, insulin, and full growth medium to
induce Tcf/Lef transcriptional activity strictly correlates with
their ability to induce DNA synthesis, because stimuli that
induce high levels of Tcf/Lef transcription also promote DNA
synthesis (e.g. EGF and growth medium), whereas those stim-
uli that do not induce Tcf/Lef-mediated transcription (e.g. in-
sulin) do not promote DNA synthesis. The exception to this
apparent correlation between TOPFLASH response and DNA
synthesis involves serum stimulation, which induced strong
integrated TOPFLASH signal but failed to promote DNA syn-
thesis. Taken together, stimuli that induce DNA synthesis also
promote Tcf/Lef transcriptional activity (e.g. EGF), but the
converse is not necessarily true (e.g. serum). Therefore, Tcf/Lef
transcriptional activity is by itself insufficient to promote
proliferation.
Tcf/Lef Transcriptional Activity Is Required for EGF-medi-
ated DNA Synthesis—Although Tcf/Lef transcriptional activity
is not sufficient for proliferation, we examined whether its
activity is required for cell cycle progression using dominant-
negative Tcf4. MCF-10A cells were infected with retrovirus
encoding FLAG-tagged, dominant-negative Tcf4 (pPGS-FLAG-
N-Tcf4), and expression was confirmed by Western blot (data
not shown) and immunofluorescence (Fig. 4A). Exogenous dom-
inant-negative Tcf4 was clearly identifiable among N-Tcf4-
infected cells because of distinct anti-FLAG staining, which
was only observed at background levels in control (pPGS)-
infected cells. Staining with anti-Tcf4 antibody revealed that
both endogenous Tcf4 and FLAG-N-Tcf4 were localized to the
nucleus, and expression of the dominant-negative construct
greatly enhanced the intensity of anti-Tcf4 stain, consistent
with the expected overexpression of this exogenous protein.
To determine the role of Tcf/Lef in cell cycle progression,
EGF- and growth medium-induced DNA synthesis were meas-
ured by assessing BrdU incorporation in control and dominant-
negative Tcf4-infected MCF10A cells. Because the multiplicity
of infection was less than 1, BrdU uptake was observed among
both cell populations upon stimulation (Fig. 4B). Importantly,
co-staining for FLAG revealed that cells clearly expressing
FLAG-tagged, dominant-negative Tcf4 never incorporated
BrdU, showing a strict Tcf/Lef requirement for DNA synthesis.
More quantitatively, both growth medium and EGF stimu-
lation induced BrdU uptake in pPGS-infected cells (Fig. 4C).
Consistent with thymidine incorporation in uninfected cells
(Fig. 3C), growth medium was more mitogenic than EGF alone.
In the case of pPGS-N-Tcf4-infected cells, the fraction of nu-
clei positive for BrdU was determined among FLAG-positive
and FLAG-negative subpopulations. Although the FLAG-neg-
ative cells incorporated BrdU at levels similar to control pPGS-
infected cells, growth medium- and EGF-mediated BrdU incor-
poration in FLAG-positive cells was inhibited completely. This
result quantitatively demonstrates that inhibition of Tcf/Lef-
mediated transcription thwarts EGF-mediated S phase
progression.
In addition to Tcf/Lef transcriptional activity, EGF induces
other signaling pathways that regulate cell proliferation, in-
cluding the ERK pathway. To verify that dominant-negative
Tcf4 inhibited EGF-mediated DNA synthesis by specifically
blocking Tcf/Lef signaling rather than by more globally affect-
ing EGF receptor signaling, we examined EGF-mediated
tyrosine phosphorylation and ERK signaling among control
pPGS-infected cells and pPGS-N-Tcf4-infected cells. Anti-
phosphotyrosine Western blotting revealed that EGF receptor
(
180 kDa) becomes heavily tyrosine-phosphorylated within
15 min of EGF stimulation in pPGS-infected cells and that
infection with pPGS-N-Tcf4 alters neither the magnitude nor
the dynamics of EGF receptor phosphorylation (Fig. 5). Simi-
larly, ERK1/2 undergoes rapid and sustained dual phosphoryl-
ation after EGF stimulation in both pPGS- and pPGS-N-Tcf4-
infected cells. Expression of FLAG-tagged, dominant-negative
Tcf4 was confirmed by Western blot (Fig. 5) and immunofluo-
rescence (data not shown). Taken together, this confirms that
the inhibitory effect of dominant-negative Tcf4 on proliferation
is specifically due to inhibition of EGF-mediated Tcf/Lef tran-
scriptional activity.
EGF-mediated Activation of Tcf/Lef Transcriptional Activity
Is Upstream of Cyclin D1 Promoter Activity—Upstream of S
phase entry, cyclin D1 regulates passage through mid-G1 phase
of the cell cycle and is also a Tcf/Lef target gene (36, 37).
Therefore, we examined whether Tcf/Lef regulates cyclin D1
induction using the 1745CD1 reporter that monitors cyclin D1
promoter activity (39). In serum-starved MCF-10A cells, stim-
ulation with growth medium initiated cyclin D1 reporter activ-
ity at 
12 h (Fig. 6A). The observation that the time course of
TOPFLASH activation (Fig. 1B) precedes timing of cyclin D1
promoter activity is consistent with, but does not prove the fact,
that Tcf/Lef lies upstream of cyclin D1 upregulation.
To determine whether Tcf/LEF activity is in fact required for
cyclin D1 promoter activity, different amounts of dominant-
negative Tcf4 (pcDNA-myc-N-Tcf4) balanced with empty vec-
tor (pcDNA) were co-transfected, and cyclin D1 promoter activ-
ity measured 12 h after growth medium stimulation. The
reporter response was abolished in MCF-10A cells co-trans-
fected with myc-N-Tcf4 in a dose-dependent fashion (Fig. 6B),
establishing a causal link between Tcf/Lef activity and cyclin
D1 promoter activity.
DISCUSSION
In this work, we demonstrate that EGF stimulates Tcf/Lef
transcriptional activity in normal mammary epithelial cells
and that its transcriptional activity is essential for EGF-medi-
ated cyclin D1 induction and DNA synthesis. Thus, expression
of dominant-negative Tcf4 inhibits EGF-mediated Tcf/Lef tran-
scriptional activity and also blocks EGF-mediated BrdU up-
take. To our knowledge, this report offers the first demonstra-
tion that a specific growth factor, other than Wnt ligands,
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stimulates cell cycle progression in a Tcf/Lef-dependent man-
ner in an untransformed epithelial cell line.
Although complex medium containing fetal calf serum has
been shown to stimulate TOPFLASH reporter (29), the only
specific, non-Wnt growth factors implicated in Tcf/Lef signaling
among normal epithelial cells are HGF and Gas6 (34, 54).
Although Gas6 was shown to induce both Tcf/Lef-mediated
transcription and proliferation, these results were correlative
and did not establish a mechanistic role for -catenin signaling
in cell proliferation. Nevertheless, a role for Tcf/Lef in HGF-
mediated proliferation may be inferred cautiously from the
finding that overexpression of oncogenic MET and RON (recep-
tors for HGF and macrophage-stimulating protein/HGF-like
protein, respectively) induces transformation in a Tcf/Lef-de-
pendent manner (55). Because these studies involved overex-
pression of oncogenic receptors, it is difficult to conclude
whether HGF-mediated Tcf/Lef signaling will have similar
functional significance in normal cells. Indeed, our findings
suggest that such extrapolation may prove quantitatively in-
accurate, especially in the case of insulin-induced Tcf/Lef sig-
naling. Insulin and insulin-like growth factor I stabilize -cate-
nin and induce TOPFLASH reporter activity in cancer cell lines
with constitutive defects in -catenin degradation machinery
(32). However, our observations reveal that, in the context of
normal -catenin regulation, insulin stimulates Tcf/Lef tran-
scriptional activity only to a relatively minor extent and to a
level that is insufficient to promote cell cycle activity.
Interestingly, our results suggest a correlation between the
level of EGF- and insulin-mediated Tcf/Lef transcriptional ac-
tivity and their differential ability to phosphorylate GSK3 at
serine 9. Serine 9 phosphorylation inhibits GSK3 kinase ac-
tivity toward primed substrates (49). However, published re-
ports support both the possibility that -catenin is a primed
substrate (50, 51) and the possibility that it may be a non-
primed substrate (49, 52) for GSK3. In vitro kinase assays
have demonstrated that mutations in GSK3 that abolish ki-
nase activity toward primed substrates do not affect its activity
toward -catenin (49). Consistent with this finding, Wnt-medi-
ated stabilization of -catenin signaling does not coincide with
phosphorylation of GSK3 at serine 9, whereas insulin-medi-
FIG. 4. Dominant-negative Tcf4 blocks DNA synthesis. A, both
endogenous Tcf4 and exogenous N-Tcf4 localize to cell nuclei. MCF-
10A cells were retrovirally infected with either the empty vector (pPGS)
or FLAG-tagged dominant-negative Tcf4 (pPGS-N-Tcf4) and co-
stained for Tcf4 and FLAG. Among pPGS-infected cells, endogenous
Tcf4 (green) was visible in the nucleus (DAPI, blue), whereas an anti-
FLAG antibody (red) revealed only background staining within the cell
body. Among cells infected with pPGS-N-Tcf4, anti-FLAG staining
produced intense signal from cell nuclei, demonstrating that dominant-
negative Tcf4, like its endogenous counterpart, localizes to the nucleus.
Consistently, Tcf4 staining in N-Tcf4-expressing cells was signifi-
cantly more intense than endogenous Tcf4 levels in pPGS-infected cells.
B, N-Tcf4 completely blocks BrdU incorporation at a single-cell level.
MCF-10A cells were infected with either pPGS or pPGS-N-Tcf4 at a
multiplicity of infection less than 1. After serum starvation, the cells
were stimulated to re-enter the cell cycle with either full growth me-
dium, serum-free medium, or serum-free medium supplemented with
20 ng/ml EGF. After a 6-h pulse with BrdU, the cells were co-stained
with anti-FLAG antibody (red), anti-BrdU (green) antibody, and DAPI
(blue). Images depict immunofluorescence results of EGF-stimulated
cells. The BrdU and FLAG images have been superimposed to demon-
strate that cells incorporating BrdU never express FLAG-tagged N-
Tcf4. The arrowheads denote FLAG-positive cells, and the asterisks
denote BrdU-positive cells. C, quantification of immunostaining reveals
that N-Tcf4 completely inhibits BrdU incorporation in MCF-10A cells.
The fraction of nuclei positive for BrdU was quantified from immuno-
stained samples of cells treated with serum-free medium (open bars),
growth medium (black bars), and EGF (hatched bars) medium as de-
scribed above for B. Among pPGS-infected cells, both growth medium and
EGF substantially increase the fraction of cells incorporating BrdU.
Within the population targeted for infection by pPGS-N-Tcf4, those cells
lacking expression of FLAG-tagged, N-Tcf4 responded to growth me-
dium and EGF similar to pPGS-infected cells. Notably, FLAG-positive
cells failed to incorporate BrdU upon stimulation by either EGF or growth
medium. The error bars are  S.E. (n  6). The asterisk denotes p 	 0.05
(Student’s t test) in comparing delineated data pairs.
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ated phosphorylation of GSK3 at serine 9 correlates with its
ability to activate a primed substrate, glycogen synthase (52).
Taken together, these reports support a model where -catenin
is a nonprimed substrate whose phosphorylation is regulated
by GSK3, but not in a serine 9 phosphorylation-dependent
manner. In contrast, other reports have identified members of
the casein kinase I family as priming kinases that are required
for GSK3-mediated phosphorylation of N-terminal -catenin
serine residues (50, 51). Thus, assuming -catenin stabilization
via inhibition of GSK3 activity plays a crucial role in EGF-
mediated Tcf/Lef transcriptional activation as it does in Wnt
signaling, the mechanistic significance of our observed correla-
tion between the level of phosphorylation of GSK3 at serine 9
and the intensity of Tcf/Lef transcriptional activity will depend
on whether EGF employs a primed or nonprimed mechanism to
affect -catenin stabilization. Further quantitative experi-
ments to test this and other hypotheses regarding the mecha-
nisms by which EGF stimulates Tcf/Lef transcriptional activity
are underway.
Although the mechanisms connecting EGF stimulation to
Tcf/Lef transcriptional activity remain to be deciphered, this
work focused on the essential role that EGF-mediated Tcf/Lef
activation plays in stimulating DNA synthesis. Further up-
stream within the cell cycle, we show that EGF-mediated in-
duction of cyclin D1 promoter activity was blocked by expres-
sion of dominant-negative Tcf4, consistent with the fact that
cyclin D1 is a putative target gene for Tcf/Lef transcription
factors (36, 37).
Importantly, although Tcf/Lef transcriptional activity is es-
sential for G1/S phase progression, it alone is insufficient for
DNA synthesis. Thus, serum induces TOPFLASH reporter sig-
nal but does not elicit DNA synthesis, clearly underscoring that
other signaling pathways, such as PI3K and ERK, are likely to
be important for the ultimate mitogenic response. Some clues
to how this combination of signals impinges on cell cycle regu-
lation are beginning to emerge. An important point of conver-
gence may involve the upregulation of cyclin D1 during late G1
phase of the cell cycle. The cyclin D1 promoter contains both
Tcf/Lef-binding sites that are essential for -catenin respon-
siveness and Ets and CREB sites that are essential for Ras-
FIG. 5. Dominant-negative Tcf4 does not affect EGF-mediated
EGF receptor and ERK phosphorylation. MCF-10A cells were
plated at a subconfluent density (1  105 cells/35-mm dish), allowed to
adhere for 24 h, and then retrovirally infected at a multiplicity of
infection of 1 with empty vector (pPGS) or dominant-negative Tcf4
(pPGS-N-Tcf4). Forty-eight hours after plating, the cells were serum-
starved for 24 h, stimulated with 20 ng/ml EGF, and then lysed at
indicated times afterward. The lysates were analyzed by Western blot
using anti-phosphotyrosine and anti-phospho-ERK 1/2 antibodies. Ex-
pression of dominant-negative Tcf4, as confirmed by an anti-FLAG blot,
did not affect either the magnitude or the dynamics of EGF receptor
tyrosine phosphorylation (
180-kDa band shown) and ERK phospho-
rylation. Furthermore, probing for total ERK2 revealed that expression
level of this signaling protein was unaffected by dominant-negative
Tcf4 expression. An anti-actin blot demonstrated equal loading of
cell lysate.
FIG. 6. Tcf/Lef involvement in cyclin D1 promoter activity. A,
growth medium treatment of MCF-10A cells stimulates cyclin D1 pro-
moter activity. MCF-10A cells were co-transfected with 1 g of
1745CD1 reporter and 0.1 g of pRL-TK. After serum starvation, the
cells were stimulated with growth medium, and luciferase:Renilla lu-
ciferase signal was monitored at different times. Maximum promoter
activity occurred at 12 h after stimulation. B, dominant-negative Tcf4
blocks induction of cyclin D1 promoter activity. MCF-10A cells were
transfected with 1 g of 1745CD1 reporter, 0.1 g of pRL-TK, and
different amounts (0, 0.05, 0.1, and 0.5 g) of dominant-negative Tcf4
(N-Tcf4) in balance with empty pcDNA vector (0.5, 0.45, 0.4, and 0 g,
respectively). Following serum starvation, the cells were stimulated
with growth medium for 12 h, and the luciferase:Renilla luciferase
signal was measured. Increasing the dose of N-Tcf4 reduced the in-
duction of cyclin D1 promoter activity. The error bars are S.E. (n 2),
and the asterisk denotes p 	 0.05 (Student’s t test).
FIG. 7. Proposed model for the strict requirement of Tcf/Lef
signaling for EGF-mediated cell cycle progression. EGF-induced
progression from G1 into S phase is controlled by cyclin D1 upregulation
and is known to require signals such as ERK. Here, we report that EGF
also induces Tcf/Lef-mediated transcription and that this transcrip-
tional activity is essential for cyclin D1 upregulation and DNA synthe-
sis. Other studies have suggested that Tcf/Lef transcription may re-
quire PI3K/IKK and/or PKC (52, 56). Although ERK signaling is not
affected by inhibition of Tcf/Lef transcription, ERK may either lie
upstream of /-catenin:Tcf/Lef transcription or act as a parallel signal.
Taken together, both Tcf/Lef signaling and parallel signals such as ERK
may cooperate to upregulate cyclin D1, which leads to cell cycle pro-
gression and, ultimately, cell proliferation.
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mediated activation (36). Studies using cyclin D1 promoter
reporters carrying mutations in Tcf/Lef, Ets, and/or CREB sites
revealed that exogenous expression of a stabilized -catenin
mutant stimulates cyclin D1 promoter activity independent of
Ets/CREB sites, whereas RasV12-mediated reporter stimula-
tion is independent of the Tcf/Lef sites. Yet, maximal response
was observed only when all sites were intact. Hence, these
findings argue for an additive effect of Ras and -catenin sig-
naling on cyclin D1 promoter activity. More recently, PI3K has
been implicated in regulating Tcf/Lef-dependent cyclin D1 in-
duction, as inhibition of PI3K or its downstream target IKK
thwarts serum-mediated induction of cyclin D1 (56). Further-
more, the sensitivity of cyclin D1 induction to PI3K/IKK sig-
naling was traced to a single Tcf-binding site on the cyclin D1
promoter.
Whether working additively with Ras-mediated signals, pos-
sibly including ERK, or synergistically via PI3K, Tcf/Lef tran-
scriptional activity seems to be essential for EGF-mediated
DNA synthesis, since blocking Tcf/Lef transcriptional activity
using a dominant-negative Tcf4 inhibits EGF-mediated DNA
synthesis (Fig. 7). In addition to the /-catenin:Tcf/Lef signal,
other canonical growth factor signals, such as ERK, are crucial
mediators of cell cycle activity (57). Here, we demonstrate that
inhibition of Tcf/Lef transcription by dominant-negative Tcf4
does not affect EGF-mediated activation of the ERK pathway
(Fig. 5). Thus, ERK signaling is not downstream of Tcf/Lef-
mediated transcription; however, the ERK pathway may work
synergistically with Tcf/Lef signaling to provide multiple, es-
sential signals that initiate cell cycle progression. Alterna-
tively, ERK signaling may lie upstream of Tcf/Lef signaling.
Although current work is focused on understanding the rela-
tionship among ERK, Tcf/Lef signaling, and cell cycle progres-
sion, our data demonstrate that Tcf/Lef-mediated transcription
is one of several intracellular signals that are essential for cell
cycle progression.
Taken together, our findings in MCF-10A normal mammary
epithelial cells, along with recent reports in a range of stem
cells (19, 22, 24, 26, 27), underscore the important role /-
catenin:Tcf/Lef signaling plays in normal cell proliferation. On
the other extreme, mutations that constitutively aggrandize
-catenin nuclear activity lead to transformation (5). Thus,
finding strategies that attenuate hyperactive -catenin signal-
ing in cancer cells (8, 9, 15–18) while minimizing deleterious
effects in normal cells will clearly be important to the success of
this family of therapeutic strategies.
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